Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ERCC3 MCP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ERCC3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Ferric Citrate Coordination Complex Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
ferric citrate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Sumatriptan Succinate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
sumatriptan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Lurasidone Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
lurasidone: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Bimatoprost Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
bimatoprost: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Latanoprost Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
latanoprost: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Eribulin mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
eribulin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ERCC2 MCP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ERCC2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Irinotecan Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
irinotecan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
ERCC1 MCP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for ERCC1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
EPHB4 MCP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for EPHB4, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
EPHB3 MCP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for EPHB3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.